Cannabis Is Not an Established Treatment for Pulmonary Fibrosis
Pulmonary fibrosis causes permanent scarring and thickening of lung tissue. As the lungs become stiffer, breathing can become increasingly difficult, often accompanied by a persistent dry cough, fatigue, unintended weight loss, muscle and joint pain, and clubbing of the fingers or toes. The disease may progress slowly or worsen rapidly, depending on its cause and the individual patient.
What causes pulmonary fibrosis?
Pulmonary fibrosis can develop after exposure to pollutants or workplace dust, certain medicines, radiation therapy, autoimmune disease, or other forms of lung injury. In many cases, no clear cause is found; this form is known as idiopathic pulmonary fibrosis. The condition itself is not a direct cause of lung cancer, although some risk factors—such as smoking or occupational exposure—may contribute to more than one lung disease. The Mayo Clinic overview of pulmonary fibrosis describes the disease, its symptoms, and its varied causes.
How pulmonary fibrosis is treated
Treatment depends on the type and severity of fibrosis. Doctors may recommend antifibrotic medicines, including pirfenidone or nintedanib for idiopathic pulmonary fibrosis, as well as supplemental oxygen, pulmonary rehabilitation, treatment of related conditions, and—when appropriate—evaluation for a lung transplant. These approaches may slow disease progression or improve quality of life, but existing scar tissue cannot be repaired. The Mayo Clinic’s treatment guidance provides an overview of current diagnostic and supportive options.
What does the evidence say about cannabis?
Cannabis and cannabinoids have been studied for pain, nausea, appetite loss, and some other symptoms. However, there is no established clinical evidence that medical cannabis reverses pulmonary fibrosis, prevents scarring, or slows the underlying disease. The 2014 review “Effects of smoking cannabis on lung function” examined respiratory effects rather than demonstrating cannabis as a treatment for pulmonary fibrosis. The report cited in the earlier version of this article does not provide evidence equivalent to a controlled clinical trial showing that cannabis treats the disease.
The method of use also matters. Smoking cannabis exposes already damaged lungs to irritants and other combustion products. The Centers for Disease Control and Prevention’s information on cannabis and lung health notes that cannabis smoke contains many of the same toxins, irritants, and carcinogens found in tobacco smoke and is associated with cough, mucus production, and bronchitis. The American Lung Association likewise cautions against smoking marijuana and says that the effects of vaping cannabis on the lungs remain insufficiently understood.
Edibles and other noninhaled products avoid smoke, but that does not make them proven treatments for pulmonary fibrosis. They can also cause side effects, interact with prescription medicines, and deliver unpredictable doses. Cannabis use may lead to dependence in some people, so it should not automatically be considered safer or more effective than opioid or other prescription therapies.
The bottom line
Patients with pulmonary fibrosis should not replace antifibrotic treatment, oxygen therapy, pulmonary rehabilitation, or specialist care with cannabis. Anyone considering cannabis for pain, anxiety, sleep problems, appetite loss, or other symptoms should discuss the potential benefits and risks with a pulmonologist or other qualified healthcare professional. Avoiding smoke and aerosol exposure is especially important for people with existing lung disease, while research continues into whether specific cannabinoid medicines have any useful role in symptom management.
